The present disclosure is in relation to the use of a composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with pharmaceutical excipient(s), in management of broncho- constrictive conditions such as Allergic Rhinitis, Asthma, and Chronic obstructive pulmonary disease (COPD).